Skip to content
Medical Health Aged Care, National News Current Affairs

Professor Christine Kilpatrick appointed as Commission Chair

ACSQHC 3 mins read

3 April 2024
FOR IMMEDIATE RELEASE

The Australian Commission on Safety and Quality in Health Care (the Commission) welcomes the appointment of Professor Christine Kilpatrick AO as the Commission’s new Board Chair for a five-year term.

Minister for Health and Aged Care, the Hon Mark Butler MP, confirmed Professor Kilpatrick’s appointment as Commission Chair, effective 1 April 2024. The Commission leads and coordinates safety and quality improvements across the Australian healthcare system.

 

Christine has served as a non-executive member of the Commission’s Board since July 2023. She has a distinguished career, including healthcare management experience spanning 20 years as a senior executive including 15 years as a chief executive, most recently at The Royal Melbourne Hospital.

 

Prior to these executive appointments, Christine was a neurologist specialising in epilepsy, working in both public and private practice.

 

Professor Kilpatrick is also a board member of Healthdirect Australia and the Florey. She has previously served on the board of HealthShare Victoria, the Victorian Comprehensive Cancer Centre (VCCC) Alliance and as Chair of the Doherty Institute and the Victorian Quality Council (VQC). She is an Enterprise Professor at the Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne.

 

A highly respected health leader, Professor Kilpatrick was awarded a Centenary Medal in 2001, was appointed an Officer of the Order of Australia in 2019 and was recipient of the Distinguished Fellow’s Award, Royal Australasian College of Medical Administrators in 2017.

 

The Commission’s CEO, Conjoint Professor Anne Duggan, paid tribute to outgoing Chair, Professor Villis Marshall AC, who was first appointed to the role of Board Chair in 2013.

 

“Professor Villis Marshall has made a significant contribution during a remarkable period of change in the healthcare sector. Under his leadership, the Commission worked with Professor Marshall to deliver system-wide improvements in safety and quality standards, medication safety, healthcare variation and infection control, among other achievements.

 

“Professor Marshall leaves an incredible legacy at the Commission, as he hands the baton to incoming Chair Professor Kilpatrick to continue to drive meaningful and transformative improvements to the safety and quality of health care.”

 

Professor Duggan added: “The Commission is delighted to welcome Professor Kilpatrick as Chair, as we turn our focus to priorities such as clinical governance, reducing low value care and improving sustainability within the healthcare system.

 

“Professor Kilpatrick brings to the Commission a deep understanding of health care from her breadth of experience, and we look forward to benefiting from her guidance and insights as we work together over the next five years.”


Minister Butler also confirmed the appointment of several Commission Board Members, effective 1 April 2024, including:

 

  • Professor Jeffrey Braithwaite – a leading health services and systems researcher with a strong international reputation and with deep knowledge of innovation and system reform culture.

 

  • Dr Alicia Veasey – a Torres Strait Islander obstetrician and gynaecologist with significant experience in First Nations advocacy in health care.

 

  • Ms Leanne Wells – a respected health advocate and former longstanding CEO of the Consumers Health Forum of Australia, who brings consumer advocacy and extensive governance experience.

 

  • Dr Helena Williams (reappointment) – a longstanding Board Member since 2012 with expertise in general practice as a practising GP, which is critical to the Commission’s focus on Primary Care.

 

Professor Duggan noted: “The incoming Board Members bring diverse experience and fresh perspectives, and we welcome their addition to the Board.”

 

ENDS

 

 

Media enquiries        

M: 0491 217 641 |  E: media@safetyandquality.gov.au 

 

 


About us:

About the Commission

The Australian Commission on Safety and Quality in Health Care is an Australian Government agency that leads and coordinates national improvements in the safety and quality of health care based on the best available evidence. By working in partnership with patients, carers, clinicians, the Australian, state and territory health systems, the private sector, managers and healthcare organisations, the Commission aims to ensure that the health system is better informed, supported and organised to deliver safe and high-quality care. www.safetyandquality.gov.au

 

The Commission is part of the Health portfolio of the Australian Government. Established in 2006 by the Council of Australian Governments, it has been an independent statutory authority since 2011 and is funded jointly by the Australian Government and state and territory governments. The Commission’s role, functions and responsibilities are governed by the National Health Reform Act 2011.

 

 

Media

More from this category

  • Medical Health Aged Care
  • 31/10/2024
  • 17:55
Kyowa Kirin Co., Ltd.

Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company’s 2030…

  • Contains:
  • Food Beverages, National News Current Affairs
  • 31/10/2024
  • 16:12
Swifty's

Celebrate the Silly Season with these Sensational Sips for Guilt-Free Fun

With the festive season fast approaching, it’s time to start thinking about holiday entertaining – and what better way to offer your guests a…

  • Contains:
  • Medical Health Aged Care
  • 31/10/2024
  • 12:10
MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study,…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.